| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001659 | Urologic Oncology: Seminars and Original Investigations | 2008 | 7 Pages |
Abstract
Of the molecular modifications described for renal carcinoma, aberrations in the p16 gene are frequent. In these patients, methylation of the p16 gene promoter seems to afford a protective effect against the risk of death.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Marta Vidaurreta, M. Luisa Ph.D., M. Teresa M.D., Carmen Ph.D., Sara Rafael, Silvia Veganzones, Jesus M.D., Julia M.D., Angel M.D., Manuel M.D.,